Date: 26,	/05/2021
-----------	----------

Your Name: DEBORA COMPARE

Manuscript Title: AUTOIMMUNE HEPATITIS FOLLOWING SARS-CoV-2 VACCINE: MAY NOT BE A CASUALTY.

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present	Time frame: Since the initi  X None	ai planning of the work
	manuscript (e.g., funding,	Carlo A Members	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	X None	
	Constitute in the constitution of the constitu		

5	Payment or honoraria for	X None	The second of th
	lectures, presentations, speakers bureaus, manuscript writing or		
0.00	educational events		
6	Payment for expert testimony	X None	
		A	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
	Periamo		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
8	group, paid or unpaid		
11	Stock or stock options	X None	
1 2			
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests .		

Desar porce

Date: 26/05/2021	
Your Name: GERARDO NARDONE	•
Manuscript Title: AUTOIMMUNE HEPATITIS FOLLOWING SARS-CoV-2 VACCINE: MAY	NOT BE A CASUALTY.
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work   ;
1	All support for the present manuscript (e.g., funding,	X None	
	provision of study materials,		
	medical writing, article	•	·
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X	Sofar, Alfasigma
	any entity (if not indicated		
	in item #1 above).	N. N. S.	
3	Royalties or licenses	X None	
			The second of th
4	Consulting fees	X None	

5	Payment or honoraria for	X		• •			Ma	alesci,	Taked	а			**			
	lectures, presentations,			1.24	٠,,		1	. ;	: ":::;		e babili.				- 27	17:12:1:
	speakers bureaus,	-			: :	-:	1 100	1 1 1 1		1.7	. :-		-:	·:		
	manuscript writing or						: :::	1111			10 -				44	
.:-	educational events		14.	77		<u>::</u>	1 1:2			<u> </u>			·. · ·		4, 1	
6	Payment for expert	X	None	<u> </u>												
	testimony			•							•					
7	Support for attending	X	None	<u> </u>		· ,			::		·	: :		- 11	*A +	•
	meetings and/or travel		·	<u>. 44</u>		·	1::.	- 11	<u>. :</u>		<u> </u>	<del></del>			<del> </del>	
		j.	: .		•			:						;;·	1.	
. :					- : :	<del></del> -	+	- 17		- <u> </u>	:				··· :-	<del>-1.: }</del>
				٠.	. :				:	1. 1			- 2:	da.	;	
8	Patents planned, issued or pending	Х	None	2												
9	Participation on a Data	<u> </u>	None	•	· ·	. :	4				1				211	<u>-111</u>
	Safety Monitoring Board or	·				111		· .	1.							
	Advisory Board	-		•		<u>:</u>	<u> </u>	::	: ::::		<u>: :</u>	:	<u> </u>	<u>.::::::::::::::::::::::::::::::::::::</u>		<u> </u>
10	Leadership or fiduciary role	X	None	<u> </u>	•											
	in other board, society,	$\vdash$	·				1						e .		<u> </u>	
	committee or advocacy group, paid or unpaid															
11	Stock or stock options	x	None	<b>3</b>		•	<del> </del> -	•				· :	1.1	.:.	.:	
·	Stock of Stock options		140110	<u>-</u>		<del></del>	+						<del>.</del>	· · · · · · · · · · · · · · · · · · ·	^	
		-	· -,	<del></del>		· · · · ·			1.2		<u> </u>			· · · ·	- 11	-:
12	Receipt of equipment,	X	None	<u> </u>			1				-			<del>.</del>		
	materials, drugs, medical															
	writing, gifts or other															
	services	$oldsymbol{\perp}$														
13	Other financial or non-	Х	None	<u> </u>				· ·		:						
:	financial interests				· · · · · ·			:	: ::				- ::-			
		1			. ::		:."			:::			· · · · ·		5.5 :	. :: .

Date:	26/	05/	2	0	2	1	

Your Name: ALBA ROCCO

Manuscript Title: AUTOIMMUNE HEPATITIS FOLLOWING SARS-CoV-2 VACCINE: MAY NOT BE A CASUALTY.

Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X None	
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	X None  X None	36 months
4	Consulting fees	X None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	X None  X None
7	Support for attending meetings and/or travel	X None
8	Patents planned, issued or pending	X None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None
11	Stock or stock options	X None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None
13	Other financial or non- financial interests	X None

Date: 26/05/202:	Date:	26	05/	2021
------------------	-------	----	-----	------

Your Name: COSTANTINO SGAMATO

Manuscript Title: AUTOIMMUNE HEPATITIS FOLLOWING SARS-CoV-2 VACCINE: MAY NOT BE A CASUALTY.

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X None	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations,	. X None		
	speakers bureaus, manuscript writing or educational events			
6	Payment for expert testimony	X None	•	
7	Support for attending meetings and/or travel	X None		
8	Patents planned, issued or pending	X None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None		
11	Stock or stock options	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None		
13	Other financial or non- financial interests	X None		